YD Bio Ltd. (NASDAQ: YDES) is Pioneering the Next Era of Cancer Diagnostics and Advanced Eye Care While Driving Commercial Revenue RIGHT NOW.

YD Bio Ltd. (NASDAQ: YDES) is setting itself apart by turning breakthrough science into commercial solutions. The company’s OkaiDx™ liquid biopsy platform now enables early detection of pancreatic, colorectal, and breast cancers across most of the U.S., combining non-invasive testing with at-home blood collection and telehealth support. At the same time, YDES’s FDA-cleared Exovisse® contact lenses and artificial tears are generating near-term revenue while laying the foundation for next-generation regenerative therapies. With 20-year strategic agreements with EG Biomed and 3D Global Biotech, YDEShas secured exclusive access to advanced molecular diagnostics and stem cell-derived exosome therapies, positioning itself at the forefront of two of healthcare’s fastest-growing markets.

YDES isn’t waiting for approvals or hypothetical breakthroughs — it’s already in the market, scaling its diagnostics and eye care solutions while building a robust pipeline for the future. From U.S. expansion with a new California operations hub to growing clinical validation of its early cancer detection platform, YDES is combining execution, innovation, and strategic partnerships for long-term impact.

In 2026, YDES could redefine what it means to be a biotech leader. By turning liquid biopsy technology into a nationwide cancer detection platform and pairing it with regenerative ocular therapies, YD Bio is tackling two of healthcare’s fastest-growing markets simultaneously.

Explore how YDES is positioned at the center of two of healthcare’s fastest-growing markets.[/lin]
 
 
 
 
 
 

---

Just For You

3 Strong Dividend Growers for Income Without Rate Risk

Author: Chris Markoch. Published: 1/7/2026. 

For many income-oriented investors, buying dividend stocks means looking for utilities stocks and real estate investment trusts (REITs). These companies offer consistent payouts for regular income and typically have some of the highest yields.

These sectors come with risks, such as sensitivity to interest rates, limited earnings growth and heavy regulatory exposure. While those factors could become tailwinds instead of headwinds in 2026, the only thing investors can count on is uncertainty.

For investors who want dependable income without those constraints, a different strategy is to focus on dividend growers rather than high-yield stocks. These are companies that prioritize consistent payout increases backed by durable cash flow, pricing power and relatively low long-term business volatility.

White House Insider Warns: Prepare for Public Law 63-43 (Ad)

A little-known U.S. law is back in focus as analysts examine how existing presidential authorities could influence markets in 2026 and beyond.

In a new briefing, a former government advisor explains the historical context behind this statute, why it’s being discussed again, and how certain policy actions could reshape capital flows during America’s upcoming 250th anniversary period. The presentation focuses on preparedness, macro implications, and what investors may want to understand as events develop.See the full briefing here

What You Need to Know

• In 2026, income-focused investors should look for dividend growth supported by durable cash flow, pricing power, and recurring revenue models.
• Roper, Ecolab, and Air Products and Chemicals are examples of companies that deliver income potential without heavy exposure to interest-rate sensitivity or regulatory risk.
• Income-oriented investors benefit from long-term compounding from companies with decades of consistent dividend increases.

While their yields may start lower, the compounding effect of rising dividends can deliver superior income over time. This approach is especially appealing when interest rates remain unpredictable and economic growth is uneven across sectors.

Roper Technologies: An Asset-Light Dividend Compounder

Roper Technologies Inc. (NASDAQ: ROP) is best known as a diversified technology and industrial company. That’s reflected in its price-to-earnings (P/E) ratio of around 30x — a premium to the market average but below the stock’s historical norm.

Beyond valuation, the company’s appeal for income investors lies in its asset-light model. Roper owns a portfolio of niche software, engineered products and data analytics businesses that generate recurring revenue and enjoy high margins.

That structure produces consistent free cash flow, which management has historically used to fund disciplined acquisitions and steadily increase dividends. The business model creates an attractive setup: growth more typical of technology companies combined with the reliability of industrials.

ROP stock has a modest 0.83% dividend yield, but its payout has grown at a double-digit pace over long periods — reflecting both earnings growth (expected in the mid-single digits in 2026) and strong capital discipline. The company is a dividend aristocrat, having increased its payout for 32 consecutive years.

Ecolab: Pricing Power in Essential Services

Ecolab Inc. (NYSE: ECL) is a global provider of water, hygiene and infection-prevention solutions and services. It’s a category that’s easy to overlook but hard to replace. Water sanitation is essential to industries such as foodservice, hospitality, healthcare and manufacturing, which gives Ecolab significant pricing power and growing recurring revenue.

This pricing power has become increasingly valuable as companies face higher input costs and stricter regulatory requirements. Ecolab can pass through cost increases while maintaining margins, supporting steady earnings growth even in uncertain economic environments.

The company has raised its dividend for 33 consecutive years. Like Roper, Ecolab has a modest yield (1.09%), but it pays $2.92 per share and has grown its dividend by about 5% annually over the past three years.

Air Products and Chemicals: Contracted Cash Flow with Growth Optionality

Air Products and Chemicals Inc. (NYSE: APD) is a global leader in industrial gases, supplying oxygen, nitrogen, hydrogen and specialty gases to industries such as energy, chemicals, electronics and healthcare.

What makes the company especially attractive for income investors is its contract structure. Many of the company’s projects operate under long-term, take-or-pay agreements, which provide highly visible and stable cash flow. The company has also positioned itself as a key player in hydrogen and clean energy infrastructure, offering potential long-term upside alongside its core business.

This predictability resembles that of regulated utilities but without the same direct regulatory oversight or comparable sensitivity to interest rates. As a result, APD can support a competitive dividend while continuing to invest in new growth areas.

Air Products & Chemicals became a dividend king in 2025 by raising its dividend for the 50th consecutive year. As of January 2026, the annual payout is an impressive $7.16 per share, and it has grown roughly 6.9% annually over the last three years.

Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO’s, CFO’s, COO’s and other insiders.

This email content is a sponsored message sent on behalf of Smallcaps Daily, a third-party advertiser of InsiderTrades.com and MarketBeat. 


This message is a paid advertisement for YD Bio Ltd. (NASDAQ: YDES) from Smallcaps Daily and Interactive Offers. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $13,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Smallcaps Daily or Interactive Offers. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding YD Bio Ltd. (NASDAQ: YDES) on Interactive Offers’ website for additional information about the relationship between Interactive Offers and YD Bio Ltd. (NASDAQ: YDES).


If you have questions or concerns about your subscription, feel free to email our U.S. based support team at contact@marketbeat.com.

If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.

© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103-7078. United States..

Featured Link: 5 Stocks That Could Double in 2026 (Click to Opt-In)